Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Breast cancer atlas reveals hidden subtypes to help chart course for precision oncology (opens in a new tab)

medicalxpress.com · 2026-11-03

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3
Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 8Not checkedA new molecular map of breast cancer identified novel forms of the disease and is presented as a foundation for selecting personalized treatments guided by a tumor's molecular characteristics rather than standard pathology alone.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 8Not checkedResearchers at Vanderbilt-Ingram Cancer Center generated one of the largest transcriptomic maps of breast cancer ever assembled, integrating data from more than 7,600 tumors across 22 independent studies.View evidenceHide evidence

As statedmore than 7,600 tumors across 22 independent studies

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 8Not checkedThe atlas reportedly reveals distinct tumor populations associated with different clinical outcomes, biological characteristics and therapeutic vulnerabilities, including previously hidden forms of breast cancer that differ in prognosis, biology and treatment sensitivity.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 8Not checkedThe article says estrogen receptor-low breast cancers behave more like ER-negative disease and may require different treatment considerations.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 5 of 8Not checkedThe atlas identifies subsets of HER2-positive tumors that are most dependent on HER2 signaling and could benefit from specific HER2 kinase inhibitors.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 6 of 8Not checkedThe study uncovers a hidden neuroendocrine form of breast cancer associated with worse outcomes following standard chemo-endocrine therapy and points to FGFR1 as a potential therapeutic target.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 7 of 8Not checkedThe atlas defines a biologically distinct aggressive basal-luminal progenitor subtype of triple-negative breast cancer with potential vulnerabilities to RTK/MAPK-targeted and anti-angiogenic therapies.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 8 of 8Not checkedThe researchers also created a tool that can assign tumors to subtypes using standard bulk RNA sequencing data to guide future research studies and clinical trials, and they say the next step is prospective testing of biology-guided treatment decisions.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

An integrated breast cancer transcriptomic atlas defines clinical subtypes and informs cellular origin

Cell Reports Medicine · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Selected

An integrated breast cancer transcriptomic atlas defines clinical subtypes and informs cellular origin

Cell Reports Medicine · 2026 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.